MARKET

LRMR

LRMR

Larimar Therapeutics Inc
NASDAQ
3.370
+0.300
+9.77%
After Hours: 3.350 -0.02 -0.59% 18:55 02/06 EST
OPEN
3.130
PREV CLOSE
3.070
HIGH
3.405
LOW
3.110
VOLUME
1.09M
TURNOVER
--
52 WEEK HIGH
5.37
52 WEEK LOW
1.610
MARKET CAP
280.01M
P/E (TTM)
-1.7484
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LRMR last week (0126-0130)?
Weekly Report · 5d ago
Larimar’s Pediatric Friedreich’s Ataxia Trial Termination: What Investors Should Know
TipRanks · 01/28 16:30
Weekly Report: what happened at LRMR last week (0119-0123)?
Weekly Report · 01/26 09:39
Larimar Therapeutics executes preferred stock exchange and amendment
TipRanks · 01/22 12:29
Larimar Therapeutics Announces Exchange of Common Shares for Series A Convertible Preferred Stock
Reuters · 01/22 12:02
Weekly Report: what happened at LRMR last week (0112-0116)?
Weekly Report · 01/19 09:42
Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care
Seeking Alpha · 01/16 11:17
Larimar advances nomlabofusp toward accelerated Friedreich’s ataxia approval
TipRanks · 01/12 21:50
More
About LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Webull offers Larimar Therapeutics Inc stock information, including NASDAQ: LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.